Elan still at sell for Merrill

Elan Corp. was kept at a sell by Merrill Lynch analyst Erica Whittaker after Elan posted a wider third-quarter loss than expected, in part due to lower reported Tysabri sales of $8 million than consensus forecasts of $12 million. According to the analyst, clinical checks show a cautious response reflected in Tysabri's slow launch profile in the United States and Europe. Shares of the Dublin, Ireland-based biotechnology company were down 31 cents, or 2.03%, at $14.93. (NYSE: ELN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.